This brand name is authorized in Israel
The drug XYLO-POS contains one active pharmaceutical ingredient (API):
|
1
Xylometazoline
UNII X5S84033NZ - XYLOMETAZOLINE HYDROCHLORIDE
|
|
Xylometazoline acts directly on α-adrenoreceptors but does not act on β-receptors. When used topically as a nasal decongestant, xylometazoline acts rapidly and provides long-lasting relief. Onset of action is within minutes, the decongestant effect being prolonged and lasting for up to 10 hours. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| R01AA07 | Xylometazoline | R Respiratory system → R01 Nasal preparations → R01A Decongestants and other nasal preparations for topical use → R01AA Sympathomimetics, plain |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: IL | מִשְׂרַד הַבְּרִיאוּת | Identifier(s): 5268 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
